Literature DB >> 34133976

Impact of the COVID-19 pandemic on eye strain and dry eye symptoms.

Ian J Saldanha1, Rebecca Petris2, Matthew Makara3, Prabjot Channa4, Esen K Akpek5.   

Abstract

PURPOSE: Among adult individuals with dry eye, assess the self-reported impact of the COVID-19 pandemic on (1) dry eye-related visual function, (2) reading efficiency, and (3) dry eye treatments used.
METHODS: In June-July 2020, we conducted an online survey of adults with dry eye who spent at least somewhat more time at home during the pandemic than before. Consistent with TFOS DEWS II guidelines, we categorized respondents into mild, moderate, or severe dry eye based on treatment usage.
RESULTS: We included 388 respondents: 97 respondents (25%) with mild, 80 (21%) with moderate, and 211 (54%) with severe dry eye. In all three groups, screen/reading time generally doubled during the pandemic. Reduced work-related efficiency was noted by a considerable proportion of respondents (moderate dry eye: 51%, mild: 39%, and severe: 38%). Compared with respondents with mild dry eye, respondents with moderate dry eye were considerably more likely to note worsening symptoms: eye pain (OR = 2.57, 95% CI 1.22-5.41), headache from eye symptoms (OR = 2.34, 95% CI 1.11-4.90), and difficulty concentrating because of eye symptoms (OR = 2.79, 95% CI 1.37-5.66). Respondents with moderate dry eye with Sjögren's syndrome were most likely to note these. Respondents with severe dry eye were more likely than respondents with mild dry eye to report losing access to dry eye-related treatments (OR = 2.62, 95% CI 1.36-5.03).
CONCLUSIONS: The COVID-19 pandemic-related eye strain may be impacting symptoms, performance, and ultimately employment, especially for those with moderate dry eye. This may be compounding the already-high dry eye-related societal burden.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COVID-19; Dry eye; Eye strain; Reading; Visual function

Year:  2021        PMID: 34133976     DOI: 10.1016/j.jtos.2021.06.004

Source DB:  PubMed          Journal:  Ocul Surf        ISSN: 1542-0124            Impact factor:   5.033


  7 in total

1.  The Effect and the Mechanism of Comprehensive Treatment on the Ocular Surface and the Visual Quality of Online Teachers with a Mild-to-Moderate Dry Eye Condition During the Early Phase of Coronavirus Disease 2019.

Authors:  Yan-Xi Wang; Gang-Jin Kang; Juan Zhou; Kai-Ming Li; Man-Hua Xu
Journal:  Int J Gen Med       Date:  2021-10-14

2.  Impact of COVID-19 pandemic on ophthalmic presentations to an Australian outer metropolitan and rural emergency department: a retrospective comparative study.

Authors:  King Fai Calvin Leung; Mojtaba Golzan; Chaminda Egodage; Simon Rodda; Richard Cracknell; Peter Macken; Shweta Kaushik
Journal:  BMC Ophthalmol       Date:  2022-01-28       Impact factor: 2.209

3.  Advances in Dry Eye Disease Examination Techniques.

Authors:  Yaying Wu; Chunyang Wang; Xin Wang; Yujie Mou; Kelan Yuan; Xiaodan Huang; Xiuming Jin
Journal:  Front Med (Lausanne)       Date:  2022-01-25

4.  Sleep Loss Causes Dysfunction in Murine Extraorbital Lacrimal Glands.

Authors:  Shenzhen Huang; Hongli Si; Jiangman Liu; Di Qi; Xiaoting Pei; Dingli Lu; Sen Zou; Zhijie Li
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-06-01       Impact factor: 4.925

5.  Outbreak of COVID-19-Related Myopia Progression in Adults: A Preliminary Study.

Authors:  Thitika Kohmarn; Noppadol Srisurattanamethakul; Akarapon Watcharapalakorn; Teera Poyomtip; Chotika Poolsanam
Journal:  Clin Optom (Auckl)       Date:  2022-08-04

6.  Provocation of dry eye disease symptoms during COVID-19 lockdown.

Authors:  Nutnicha Neti; Pinnita Prabhasawat; Chareenun Chirapapaisan; Panotsom Ngowyutagon
Journal:  Sci Rep       Date:  2021-12-24       Impact factor: 4.379

7.  Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients Presenting with Conjunctivitis During the COVID-19 Pandemic.

Authors:  Sezen Karakus; James Foster; Xi Dai; Anthony Gonzales; Xi Zhu; Charles Eberhart; William Hsu
Journal:  Clin Ophthalmol       Date:  2022-01-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.